• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $JAZZ alert in real time by email
    SC 13G/A 1 tv01247-jazzpharmaceuticalsp.htm SCHEDULE 13G/A jazzpharmaceuticalsplc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934
    (Amendment No.: 10)*

    Name of issuer:  Jazz Pharmaceuticals PLC

    Title of Class of Securities:  Common Stock

    CUSIP Number:  G50871105

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  G50871105

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    54,434

    7.  SOLE DISPOSITIVE POWER

    6,211,844

    8.  SHARED DISPOSITIVE POWER

    151,904

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,363,748

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    10.11%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Jazz Pharmaceuticals PLC

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    Waterloo Exchange, Waterloo Road, 5th Floor
    Dublin 4

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    G50871105

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $JAZZ alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JAZZ

    DatePrice TargetRatingAnalyst
    2/27/2026$224.00Overweight
    Barclays
    11/24/2025$188.00Buy → Neutral
    UBS
    7/15/2025$152.00Buy
    Deutsche Bank
    3/7/2025$145.00 → $179.00Neutral → Buy
    UBS
    2/26/2025Overweight → Neutral
    Cantor Fitzgerald
    2/13/2025$130.00 → $170.00Equal Weight → Overweight
    Wells Fargo
    12/12/2024$140.00 → $175.00Equal-Weight → Overweight
    Morgan Stanley
    6/5/2024$169.00Buy
    Goldman
    More analyst ratings

    $JAZZ
    SEC Filings

    View All

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    3/3/26 2:35:29 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Jazz Pharmaceuticals plc

    144 - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/27/26 4:12:50 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Jazz Pharmaceuticals plc

    10-K - Jazz Pharmaceuticals plc (0001232524) (Filer)

    2/24/26 4:10:35 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 12, 2021 - FDA Grants First of its Kind Indication for Chronic Sleep Disorder Treatment

    For Immediate Release: August 12, 2021 The U.S. Food and Drug Administration today approved a new indication for Xywav for idiopathic hypersomnia (IH) in adults. IH is an uncommon chronic sleep disorder that causes people to be excessively sleepy during the day even after a good night's sleep. Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution is already approved for the treatment of catapl

    8/12/21 4:25:43 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Mulligan Seamus bought $9,993,082 worth of Ordinary Shares (101,621 units at $98.34) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    5/13/25 6:51:34 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson Philip L was granted 15,932 units of Ordinary Shares and bought $1,435,800 worth of Ordinary Shares (12,000 units at $119.65) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/5/24 7:28:40 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

    – Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –– Expect 2026 total revenues of $4.25 to $4.50 billion –DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026."2025 was an exceptional year for

    2/24/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences

    DUBLIN, Feb. 17, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the Company will participate in the following investor conferences:TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026Fireside chat at 7:30 a.m. PT / 10:30 a.m. ET / 2:30 p.m. GMTBarclays 28th Annual Global Healthcare Conference on Thursday, March 12, 2026Fireside chat at 7:00 a.m. PT / 10:00 a.m. ET / 2:00 p.m. GMTAn audio webcast of both fireside chats will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations. A replay of the webcasts will be archived on the website for 30 days.About Jazz

    2/17/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Jazz Pharma with a new price target

    Barclays initiated coverage of Jazz Pharma with a rating of Overweight and set a new price target of $224.00

    2/27/26 8:31:30 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharma downgraded by UBS with a new price target

    UBS downgraded Jazz Pharma from Buy to Neutral and set a new price target of $188.00

    11/24/25 8:15:18 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Deutsche Bank initiated coverage on Jazz Pharma with a new price target

    Deutsche Bank initiated coverage of Jazz Pharma with a rating of Buy and set a new price target of $152.00

    7/15/25 8:41:59 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Riedel Norbert G exercised 3,415 units of Ordinary Shares at a strike of $138.08 and sold $655,680 worth of Ordinary Shares (3,415 units at $192.00) (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/2/26 5:36:59 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Financial Officer Johnson Philip L was granted 11,857 units of Ordinary Shares, increasing direct ownership by 24% to 62,223 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/2/26 5:22:03 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Pearce Samantha was granted 9,782 units of Ordinary Shares, increasing direct ownership by 23% to 52,775 units (SEC Form 4)

    4 - Jazz Pharmaceuticals plc (0001232524) (Issuer)

    3/2/26 5:19:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Financials

    Live finance-specific insights

    View All

    Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance

    – Record total revenues of $4.3 billion in 2025 (+5% YoY) and $1.2 billion (+10% YoY) in 4Q25 –– Expect to complete sBLA submission in 1Q26 under RTOR for zanidatamab in HER2+ 1L GEA –– Xywav® achieved $1.7 billion in revenue and 12% YoY growth in 2025 –– Epidiolex® achieved $1.1 billion in revenue and 9% YoY growth in 2025 –– Strong Modeyso™ launch with $37 million in revenue in first full quarter on market –– Expect 2026 total revenues of $4.25 to $4.50 billion –DUBLIN, Feb. 24, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the full year and fourth quarter of 2025 and provided financial guidance for 2026."2025 was an exceptional year for

    2/24/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026

    DUBLIN, Feb. 10, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced its fourth quarter and full year 2025 financial results will be reported on February 24, 2026, after the close of the U.S. financial markets. Company management will host a webcast at 4:30 p.m. ET / 9:30 p.m. GMT to discuss the results and provide a business and financial update.   Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. A replay of the webcast will be availa

    2/10/26 4:15:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Announces Third Quarter 2025 Financial Results and Updates 2025 Financial Guidance

    – Modeyso™ approved as the first and only treatment for recurrent H3 K27M-mutant DMG – – Zepzelca® and atezolizumab (Tecentriq®) combination approved as maintenance therapy in 1L ES-SCLC – – 3Q25 total revenues increased 7% year-over-year driven by robust growth of Epidiolex®, Xywav® and the launch of Modeyso – DUBLIN, Nov. 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced financial results for the third quarter of 2025 and updated financial guidance for 2025. "Achieving the highest revenue quarter in Jazz's history speaks to the strength of our diversified portfolio and the outstanding performance of our team. We were pleased to once again deliver solid executio

    11/5/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/13/24 5:07:58 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    9/11/23 1:33:44 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Jazz Pharmaceuticals plc (Amendment)

    SC 13G/A - Jazz Pharmaceuticals plc (0001232524) (Subject)

    2/9/23 11:25:15 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JAZZ
    Leadership Updates

    Live Leadership Updates

    View All

    Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer

    Mr. Riga brings over 25 years of commercial and operational experience with proven success leading transformative corporate development strategies and transactions DUBLIN, Jan. 8, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as chief operating and commercial officer. In that role, he directed corporate strategy including the successful sale of Chimerix to Jazz. In addition to leading the transaction process and alliance management at Chimerix, he helped navigate a complex regulatory env

    1/8/26 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Appoints Ted W. Love, M.D., to its Board of Directors

    Dr. Love, a biopharmaceutical industry veteran, brings extensive executive leadership and board experience with proven success in creating shareholder value DUBLIN, Oct. 28, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.  "We are thrilled to welcome Ted to the Board," said Renee Gala, president and CEO, Jazz Pharmaceuticals. "His proven success in the biopharmaceutical industry and track record driving scientific innovation, commercial su

    10/28/25 4:05:00 PM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors – DUBLIN, July 10, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Jazz Board of Directors has unanimously selected Renee Gala, Jazz's President and Chief Operating Officer, as the President and Chief Executive Officer, effective August 11, 2025, when she will also join the Board. She will succeed co-founder, Chairperson and CEO Bruce Cozadd, who informed the Board in December 2024 of his intent to retire as CEO upon the identification of the Company's next leader. This appointment reflects a key milestone in t

    7/10/25 7:30:00 AM ET
    $JAZZ
    Biotechnology: Pharmaceutical Preparations
    Health Care